Non-cancerous PainPPP-CareNCT05196386

Usual Care Intervention Research Evaluating the Impact of a Personalized Pharmaceutical Plan on the Duration of Opioid Treatment in Non-cancerous Pain

A study testing Admission conciliation interview, Discharge conciliation interview and Targeted pharmaceutical interview in people with Non-cancerous Pain and Opioid Use, run by University Hospital, Rouen at 1 site in France.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record

Search all trials

Trial summary

Many treatments with WHO grade III opioids are being introduced in the rheumatology department for non-cancerous pain. The duration of this treatment prescribed at discharge is often uncontrolled and sometimes leads to significant addiction. Read more about this study

Who is it for?: Ages 18 to 75 years
Conditions the study is for: Non-cancerous Pain, Opioid Use
What is being tested?: Admission conciliation interview, Discharge conciliation interview and Targeted pharmaceutical interview
Type of treatment: Lifestyle or therapy programme
Could I receive a placebo?: No, everyone receives an active treatment
How many people: 100 participants
Where: 1 siteFrance
Study dates: 6 Aug 2020to 28 Aug 2023
Phase: Interventional
Are there results?: None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

Ages 18 to 75 years
All sexes
No healthy volunteers
Adult, Older adult

Who may be able to join

Age ≥ 18 and < 75 years old when entering the rheumatology department
Hospitalization in the rheumatology department
Patient with acute non-traumatic musculoskeletal disease
Patient not taking grade III opioid treatment
Patient affiliated to a social security scheme
Patient having read and understood the information letter and signed the consent form
Patient present on a day which the pharmacy intern is present

Who cannot join

Presence of cancer, fibromyalgia, already diagnosed at inclusion
Patient does not understand French
Patient with Current or past opioid addiction
Person deprived of liberty by administrative or judicial decision

Trial locations and contacts

1 site in 1 country.

France1 site

Rouen University Hospital
Rouen

Other trials in France

About this study

The team at the local pain center recommends an average duration of 28 days for this type of pain. There is a full-time pharmacy intern in the rheumatology department.

The aim of this work is to evaluate the impact of a targeted pharmaceutical interview on the duration of the morphine treatment initiated during hospitalization.

Conditions: Non-cancerous Pain, Opioid Use
Being tested: Admission conciliation interview, Discharge conciliation interview, Targeted pharmaceutical interview

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

Admission conciliation interviewBehavioural
Previous treatment conciliation at hospital admission
Discharge conciliation interviewBehavioural
Allocated treatment during hospital stay
Targeted pharmaceutical interviewBehavioural
Specific information about treatment delivered by pharmacist

Study groups in NCT05196386
Study group	Role	What they receive
Patient with targeted pharmaceutical interview	Experimental	Specific information about treatment delivered by pharmacist Receives: Behavioral: Admission conciliation interview; Behavioral: Discharge conciliation interview; Behavioral: Targeted pharmaceutical interview
Patient without targeted pharmaceutical interview	Other	No Specific information about treatment delivered by pharmacist Receives: Behavioral: Admission conciliation interview; Behavioral: Discharge conciliation interview

What is being measured

The primary outcome is the main question the study is designed to answer.

Total duration of opioid treatment
Measured: 6 months

Secondary outcomes (2)

Rate of patients exceeding 28 days of cumulative duration of treatment
Measured: 6 months
Rate of patients exceeding 90 days of cumulative duration of treatment
Measured: 6 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

6 Aug 202028 Aug 2023

First posted19 Jan 2022
Study start6 Aug 2020
Primary completion28 Aug 2023
Study completion28 Aug 2023

Resources

Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
Other trials for Non-cancerous PainStudies of the same condition, open and under way.
More trials run by University Hospital, RouenThe sponsor's other registered studies.
What the trial phases meanHow a treatment moves from first tests in people to approval.

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design

Study type: Interventional
Phase: Phase N/A
Primary purpose: Supportive care
Allocation: Randomised
Intervention model: Parallel groups
Masking: None (open label)
Enrolment: 100 participants (actual)

IDs, dates and publications

ClinicalTrials.gov ID: NCT05196386
Sponsor's protocol ID: 2019/0025/HP
Other IDs: 2019-A00515-52
Acronym: PPP-Care
Status last verified: Sep 2025
First submitted: 4 Feb 2020
Last updated: 5 Jun 2026
Results posted: No
Data monitoring committee: No
FDA-regulated drug: No
FDA-regulated device: No

Study at a glance

From the registry record, last updated by the sponsor on 5 Jun 2026. Recruitment status is as the sponsor reported it: confirm with the study team.

Official title: Usual Care Intervention Research Evaluating the Impact of a Personalized Pharmaceutical Plan on the Duration of Opioid Treatment in Non-cancerous Pain
ClinicalTrials.gov ID: NCT05196386
Acronym / sponsor ID: PPP-Care / 2019/0025/HP
Conditions: Non-cancerous Pain, Opioid Use
Study type: Interventional
Recruitment status: Completed
Enrolment: 100 participants (actual)
Lead sponsor: University Hospital, RouenUniversity, hospital or other
Study start: 6 Aug 2020 (actual)
Primary completion: 28 Aug 2023 (actual)
Study completion: 28 Aug 2023 (actual)
First posted: 19 Jan 2022 (actual)
Results: Not posted in the source record

Clinical summary

The research question as the sponsor registered it. This describes what the study plans to test, not what it found.

The team at the local pain center recommends an average duration of 28 days for this type of pain. There is a full-time pharmacy intern in the rheumatology department.

The aim of this work is to evaluate the impact of a targeted pharmaceutical interview on the duration of the morphine treatment initiated during hospitalization.

Study design

Primary purpose: Supportive care
Allocation: Randomised
Intervention model: Parallel groups
Masking: None (open label)
Number of arms: 2

Arm	Type	Receives
Patient with targeted pharmaceutical interview	Experimental	Behavioral: Admission conciliation interview, Behavioral: Discharge conciliation interview, Behavioral: Targeted pharmaceutical interviewSpecific information about treatment delivered by pharmacist
Patient without targeted pharmaceutical interview	Other	Behavioral: Admission conciliation interview, Behavioral: Discharge conciliation interviewNo Specific information about treatment delivered by pharmacist

Who may qualify

Ages: 18 to 75 years
Sex: All
Healthy volunteers: Not accepted
Age groups: Adult, Older adult

Key inclusion criteria (7 listed)

Age ≥ 18 and < 75 years old when entering the rheumatology department
Hospitalization in the rheumatology department
Patient with acute non-traumatic musculoskeletal disease
Patient not taking grade III opioid treatment
Patient affiliated to a social security scheme

Key exclusion criteria (4 listed)

Presence of cancer, fibromyalgia, already diagnosed at inclusion
Patient does not understand French
Patient with Current or past opioid addiction
Person deprived of liberty by administrative or judicial decision

Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.

Interventions

Intervention	Type	Arms
Admission conciliation interviewPrevious treatment conciliation at hospital admission	Behavioural	Patient with targeted pharmaceutical interview, Patient without targeted pharmaceutical interview
Discharge conciliation interviewAllocated treatment during hospital stay	Behavioural	Patient with targeted pharmaceutical interview, Patient without targeted pharmaceutical interview
Targeted pharmaceutical interviewSpecific information about treatment delivered by pharmacist	Behavioural	Patient with targeted pharmaceutical interview

Primary outcome

Total duration of opioid treatment
Time frame: 6 months

2 secondary outcomes

Rate of patients exceeding 28 days of cumulative duration of treatment
Time frame: 6 months
Rate of patients exceeding 90 days of cumulative duration of treatment
Time frame: 6 months

Results and safety

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

Research links

Official record on ClinicalTrials.govLast updated by the sponsor 5 Jun 2026.

Referral and contact

AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.

Olivier VITTECOQ, Pr principal investigator

University Hospital, Rouen

Remi VARIN, Pr principal investigator

University Hospital, Rouen

Catherine CHENAILLER, Dr principal investigator

University Hospital, Rouen

1 site in 1 country: see every site and its status.

Questions about this trial

What is this clinical trial studying?

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 7 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 5 Jun 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Total duration of opioid treatment (time frame: 6 months). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT05196386.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 5 Jun 2026.